(Source: Massachusetts General Hospital) A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment Elevated HOXB13/IL17BR ratio may indicate who should receive extended treatment with letrozole 28/Jun/2013 A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after...
↧